camrelizumab + chemotherapy + lenvatinib

This combination therapy is an investigational regimen primarily studied for the treatment of advanced or unresectable hepatocellular carcinoma (HCC). It consists of three distinct therapeutic components: **camrelizumab**, a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting the programmed cell death protein 1 (PD-1) receptor; **lenvatinib**, an oral multi-receptor tyrosine kinase inhibitor (TKI) that targets vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), and other kinases to inhibit angiogenesis and tumor cell proliferation; and **chemotherapy**, which in this specific clinical context (often associated with Shenzhen Third People's Hospital) typically refers to hepatic arterial infusion chemotherapy (HAIC) using agents such as oxaliplatin and 5-fluorouracil (FOLFOX). The triplet approach aims to combine the systemic immune-restoring effects of PD-1 inhibition with the anti-angiogenic properties of lenvatinib and the localized, high-concentration cytotoxic effects of HAIC to improve objective response rates and survival outcomes in patients with liver-dominant disease.

Other names

Camrelizumab plus lenvatinib plus chemotherapyCamrelizumab + lenvatinib + HAICCamrelizumab + lenvatinib + hepatic arterial infusion chemotherapy